The SCIPIO study was the first CPC clinical trial to investigate the therapeutic effects of autologous CPCs (cardiac c-kit+ cells) in patients with ischemic cardiomyopathy [51]. The gene discussed is KIT; the disease is ischemic cardiomyopathy.